The U.S. government has begun shipping stockpiled doses of an experimental antibody drug, MBP134, from Mapp Biopharmaceutical to the Democratic Republic of Congo to combat a widening Bundibugyo Ebola outbreak. According to the U.S. Department of Health and Human Services, this shift in policy marks the first time Washington has released the treatment for clinical trials in the region rather than reserving it exclusively for American citizens.
Why is the U.S. changing its Ebola treatment strategy?
The U.S. is pivoting from a domestic-only stockpiling strategy to supporting international clinical trials to address what the Centers for Disease Control and Prevention (CDC) warns could become the worst Ebola outbreak to date. According to a Health Department spokesperson, the move aims to gather essential trial data that could inform future regulatory reviews and potential U.S. approval for the drug. This decision follows criticism regarding the dismantling of the U.S. Agency for International Development and broader cuts to regional aid, leaving the current response reliant on these new, modest contributions.
Unlike the Ebola Zaire strain, which has established vaccines and treatments, the Bundibugyo strain currently has no approved medical countermeasures. This makes the upcoming trials particularly vital for containing the spread.
How will the experimental drug trials be conducted?
The World Health Organization (WHO) confirmed that MBP134 and two Gilead Sciences antivirals—remdesivir and obeldesivir—are being shipped to the region for testing. According to the WHO, the Mapp Biopharmaceutical drug will be tested as a standalone treatment and in combination with remdesivir. Simultaneously, obeldesivir is slated for testing as a potential preventive measure. These trials are being led by the University of Oxford in coordination with the governments of Congo and Uganda, with oversight from local ethics committees and regulators.
What are the challenges for clinical trials in conflict zones?
Conducting medical research in eastern Congo presents significant logistical hurdles that differ from standard clinical environments. According to global health officials, the combination of active conflict, disrupted supply chains, and widespread mistrust of health workers complicates patient enrollment and contact tracing. Unlike traditional research settings, these trials must prioritize security and community engagement to ensure health facilities can safely administer the drugs. The WHO maintains that these trials are necessary to verify safety and efficacy before any widespread deployment of the treatments.
Comparison: Treatment vs. Vaccine Development
| Countermeasure | Status | Primary Timeline |
|---|---|---|
| Mapp/Gilead Antivirals | Shipped/Ready for trials | Coming weeks |
| Vaccine Candidates | Manufacturing/Safety tests | Phase 1 expected July |
When will vaccines become available for the outbreak?
Vaccine deployment remains further off than therapeutic trials. According to Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations (CEPI), Phase 1 trials for vaccine candidates are expected to begin in July, likely in the UK or Uganda rather than the outbreak zone itself. While CEPI is currently backing four candidates—including those from Oxford, the Serum Institute of India, and Moderna—these doses must undergo rigorous safety assessments before they can be utilized in high-risk areas.
Frequently Asked Questions
Are these Ebola treatments already FDA approved?
No. While the treatments have shown safety in earlier trials, they have not yet been proven effective against the specific Bundibugyo strain of Ebola. The current trials aim to gather this data.
Why are these trials happening in Congo?
The trials are being conducted in the outbreak region to directly address the emergency. The WHO notes that this is the third-largest Ebola outbreak on record, necessitating rapid testing in the areas where the virus is actively circulating.
How can I track the progress of these clinical trials?
Updates on trial enrollment and regulatory approvals are being coordinated by the WHO and the respective health ministries of Congo and Uganda. Official briefings from these agencies remain the most reliable source for real-time changes.
Have questions about global health policy or the latest in vaccine research? Join the discussion in the comments section below or sign up for our weekly science briefing.